PTC Therapeutics Inc. (NASDAQ:PTCT) traded up 2.2% during trading on Monday . The stock traded as high as $8.49 and last traded at $8.21, with a volume of 364,968 shares trading hands. The stock had previously closed at $8.03.

Several research firms have weighed in on PTCT. Credit Suisse Group AG set a $6.00 price objective on shares of PTC Therapeutics and gave the company a “hold” rating in a research note on Friday, August 5th. Zacks Investment Research upgraded shares of PTC Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 12th. Citigroup Inc. reiterated a “buy” rating and issued a $48.00 price objective on shares of PTC Therapeutics in a research note on Tuesday, August 2nd. Wedbush reiterated a “neutral” rating and issued a $10.00 price objective on shares of PTC Therapeutics in a research note on Friday, August 5th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of PTC Therapeutics from $18.00 to $17.00 and set a “neutral” rating on the stock in a research note on Friday, August 5th. One analyst has rated the stock with a sell rating, ten have given a hold rating and two have issued a buy rating to the company’s stock. PTC Therapeutics has an average rating of “Hold” and a consensus target price of $34.72.

The firm’s market cap is $282.89 million. The company has a 50-day moving average of $7.13 and a 200 day moving average of $9.03.

PTC Therapeutics (NASDAQ:PTCT) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.27) by $0.13. The company earned $15.40 million during the quarter, compared to the consensus estimate of $15.24 million. During the same period last year, the company posted ($1.14) EPS. The firm’s revenue was up 150.0% compared to the same quarter last year. Equities research analysts forecast that PTC Therapeutics Inc. will post ($4.95) earnings per share for the current year.

Several hedge funds and institutional investors recently bought and sold shares of PTCT. Westfield Capital Management Co. LP boosted its position in PTC Therapeutics by 49.6% in the fourth quarter. Westfield Capital Management Co. LP now owns 1,872,220 shares of the biopharmaceutical company’s stock worth $60,660,000 after buying an additional 621,079 shares during the period. BlackRock Advisors LLC boosted its position in PTC Therapeutics by 2.3% in the fourth quarter. BlackRock Advisors LLC now owns 505,966 shares of the biopharmaceutical company’s stock worth $16,393,000 after buying an additional 11,568 shares during the period. Jennison Associates LLC boosted its position in PTC Therapeutics by 5.9% in the fourth quarter. Jennison Associates LLC now owns 1,023,987 shares of the biopharmaceutical company’s stock worth $33,177,000 after buying an additional 57,092 shares during the period. Marshall Wace LLP boosted its position in PTC Therapeutics by 50.6% in the fourth quarter. Marshall Wace LLP now owns 44,410 shares of the biopharmaceutical company’s stock worth $1,439,000 after buying an additional 14,926 shares during the period. Finally, Rhumbline Advisers boosted its position in PTC Therapeutics by 8.1% in the fourth quarter. Rhumbline Advisers now owns 33,247 shares of the biopharmaceutical company’s stock worth $1,077,000 after buying an additional 2,485 shares during the period.

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.